O Canada! Lilly Claims Country’s Invalidation Of Its Patents Violates NAFTA

Lilly is seeking $500 million for revenue it would have made if Canadian courts had not ruled its Zyprexa and Strattera patents invalid; company says Canada’s new “promise utility doctrine” is targeting pharma inventions.